Dr. Keith Elkon Archives

Tag: Dr. Keith Elkon

New Trial of Promising Lupus Treatment RSLV-132 Has Finished Enrolling Patients

July 30, 2019 Resolve Therapeutics announced that it has enrolled enough patients to conduct a Phase 2a study of a potential treatment for lupus, RSLV-132. Grant support from the Lupus Research Alliance to Dr. Keith Elkon of the University of Washington supported the early work that led to the creation of the molecule RSLV-132. In lupus, […] Read More

LRA Grant Leads to New Drug Candidate RSLV-132

May 10, 2019 Grant support from the Lupus Research Alliance (then ALR) supported early work that led to a potential new drug, RSLV-132. In lupus, antibodies can target DNA’s chemical cousin RNA, which performs a variety of jobs in cells. When these antibodies encounter an RNA molecule, they attach to it, forming clusters that can […] Read More

Lupus Research Alliance Announces Translational Research Grants to Speed Development of New Treatments

NEW YORK, NY – January 10. Can “borrowed” drugs for treating other diseases protect the skin in patients with lupus? Can researchers coax the body to weed out harmful immune cells that drive tissue destruction in lupus? Those are just two of the innovative approaches for lupus therapies recognized by the Lupus Research Alliance with […] Read More

Scientists Focus on Innate Immune System as Possible Lupus Treatment Approach

January 7, 2019 The 2018 Forum for Discovery opened with a series of lectures on new research on the role of our innate immune system in lupus and how discoveries may lead to new therapies. Roles of the cGAS Pathway in Lupus Zhijian (James) Chen, PhD, Professor of Molecular Biology at the University of Texas Southwestern […] Read More